You can read Premium News stories in full if you have an Annual Subscription to the OTCToolbox website. You can read Basic News stories free of charge.
23 October 2019
Moberg Pharma has signed an exclusive South Korean distribution agreement for MOB-015, its novel topical terbinafine formulation for treating nail fungus.
4 October 2019
Taisho Pharmaceutical has signed an exclusive Japanese licensing agreement for MOB-015, Moberg Pharma's novel topical terbinafine formulation for treating nail fungus.
24 April 2019
Novartis has recruited a new chief executive officer for Sandoz, Moberg Pharma plans to revamp its management team, and the French OTC industry association, AFIPA, has a new president.
14 February 2019
Moberg Pharma is divesting its OTC business to two private-equity firms in a cash deal worth SEK1.43 billion (USD155 million). The Swedish company plans to focus on developing and commercialising MOB-015, its novel topical terbinafine formulation for treating nail fungus.
14 February 2019
Bayer Consumer Health has signed an exclusive European licensing agreement for MOB-015, Moberg Pharma's novel topical terbinafine formulation for treating nail fungus.
7 November 2018
Mundipharma has signed an exclusive agreement to commercialise Moberg Pharma's Emtrix in the Middle East and Africa, starting in 2019.
14 August 2018
Moberg Pharma has appointed Sobi's Shaw Sorooshian as vice president and chief medical officer.